indicated for OAC because of AF who undergo PCI are recommended to receive triple therapy consisting of aspirin, a P2Y12 receptor inhibitor, and an OAC, if they are not at high risk for bleeding. However, triple therapy is associated with a 3-to 5-fold increase in total bleeding complications compared with other antithrombotic therapy T he management of patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI) remains a concern. Approximately 5-10% of patients undergoing PCI have concomitant AF 1 and require long-term oral anticoagulation (OAC) therapy. Additionally, dual antiplatelet therapy (DAPT) consisting of aspirin and a P2Y12 receptor inhibitor is essential for preventing thrombotic adverse events, such as stent thrombosis (ST), after stent implantation. Thus, patients Editorial p 963